<DOC>
	<DOCNO>NCT00750295</DOCNO>
	<brief_summary>The primary objective study ass safety , tolerability activity escalate multiple dos SBR759 patient chronic kidney disease hemodialysis .</brief_summary>
	<brief_title>A Clinical Study Evaluate Safety , Tolerability Activity New Phosphate Binder ( SBR759 ) Patients With Chronic Kidney Disease Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Patients must treat maintenance hemodialysis prescribe phosphate binder . A controlled serum phosphorus . Constant dose concomitant medication . Women child bear potential must practice acceptable form birth control ( i.e . double barrier method intrauterine device plus condom , spermicidal gel plus condom ) . All female patient must negative pregnancy test screen order eligible participate study . Patient hospitalize within 30 day prior screen surgery schedule study . Patient unstable medical condition , active infection , active malignancy ( except basal cell carcinoma skin ) , history major GI tract surgery , history hemochromatosis . Patient receive received investigational drug ( currently use investigational device ) within 30 day prior screen . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Chronic kidney disease ,</keyword>
	<keyword>hemodialysis ,</keyword>
	<keyword>serum phosphorus ,</keyword>
	<keyword>phosphate binder</keyword>
</DOC>